Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants with Generalized Myasthenia Gravis (gMG)
Study Identifier:
ALXN1210-MG-319
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
Recruiting
Study Details
Medical Condition
- Generalized Myasthenia Gravis
- Unmapped
Study Drug
- Drug: Ravulizumab
Date
Jun 2023 - Jul 2026
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: n/a - n/a
Requirements Information
Sex
Female & Male
Age
n/a - n/a
Study Details
Medical Condition
- Generalized Myasthenia Gravis
- Unmapped
Study Drug
- Drug: Ravulizumab
Date
Jun 2023 - Jul 2026
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: n/a - n/a years
Requirements Information
Protocol Summary
The primary purpose of this study is to characterize the pharmacokinetics and pharmacodynamics of treatment with ravulizumab intravenous infusion in pediatric participants with gMG.
Trial Locations
Location
Status
Location
Research Site
Marseille, Unmapped, 13385
Status
Recruiting
Location
Research Site
San Francisco, CA, United States, 94143
Status
Recruiting
Location
Research Site
Bern, Unmapped, 3010
Status
Recruiting
Location
Research Site
Belgrade, Unmapped, 11070
Status
Recruiting
Location
Research Site
Los Angeles, CA, United States, 90078
Status
Recruiting
Location
Research Site
LEIDEN, Unmapped, 2333 ZA
Status
Withdrawn